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doi:10.1016/j.pedneo.2012.01.010Background: Hemangioma in infants has a benign self-limited course, but the 10% of cases with
complications need further treatment. Successful treatment with propranolol in western coun-
tries has been reported over the past few years. We evaluated the efficacy of propranolol for
treating infantile hemangioma in Taiwanese newborns and young infants.
Methods: Patients below 1 year of age treated with propanolol between November 2009 and
March 2011 were enrolled. Demographic data, clinical features, imaging findings, treatment
regimens of propranolol, and outcome were investigated.
Results: Thirteen patients were treated with propranolol at a dose of 2e3 mg/kg/day. Seven
(53.8%) patients had solitary hemangioma and six had multiple ones. The indications for treat-
ment were risk of local event in nine patients, functional risk in four, local complication in one,
and life-threatening complication in one. The median age for starting propranolol was 4
months (range: 1e11 months). Responses to propranolol, such as decolorization, regression
in tumor size, or improvement of hemangioma-associated complications were observed in
all patients within 1e2 weeks after treatment. Propranolol-associated adverse effects
occurred in two patients. One infant had occasional tachypnea, and the other had occasional
pale-looking appearance. The symptoms resolved after dosage tapering.Pediatric Hematology/Oncology, Department of Pediatrics, Taichung Veterans General Hospital,
ichung 407, Taiwan.
ail.com (J.-D. Wang).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
126 T.-C. Hsu et alConclusion: Propranolol may be a promising therapeutic modality for infantile hemangioma.
Therapeutic strategies are needed to evaluate the optimal treatment protocol and long-
term adverse effects.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Infantile hemangioma (IH) is the most common benign
vascular tumor of infancy, and its onset usually begins
during the neonatal period. The incidence is estimated at
4e5%1 and is higher in girls and premature infants.2 IH
classically manifests as a rapid proliferation phase in the
first year after birth, followed by a spontaneous involution
phase that lasts for several years.3 It usually has a self-
limited course with minimal sequelae, and the mainstay
of therapy is conservative observation. However, even
transient cosmetic disfigurement during the long involution
phase frequently induces psychological stress in the
affected children and their parents.4 Moreover, approxi-
mately 10% of IH cases need further intervention due to
local or life-threatening complications.5,6 Some IH can
cause local complications such as ulceration, pain,
bleeding, scarring, secondary infection, and permanent
disfigurement. Others may cause significant functional
impairment, vital organ compromise, or life-threatening
complications. For these complicated IH cases, systemic
corticosteroids are generally considered to be the first-line
of pharmacological therapy. Although there is a 78e89%
response rate,7 a high recurrence rate of up to 36% and
adverse effects limit its use.8 Alternative therapeutic
options, such as vincristine,9 interferon a,6 and cyclophos-
phamide,10 are used for steroid-refractory and critical
patients, but their potential toxicities are a major concern.
The dramatic response to propranolol in the treatment
of IH was first described by Le´aute´-Labre`ze et al11 in 2008,
and a number of successful cases have been reported
worldwide.12 To the best of our knowledge, the efficacy of
propranolol in Taiwanese hemangioma patients has not
been evaluated. We investigated the therapeutic effect of
propranolol in 13 Taiwanese newborns and young infants
with IH at a tertiary pediatric medical center.
2. Patients and Methods
In this retrospective observational study, we reviewed data
from Taiwanese patients, aged <1 year, diagnosed with IH
and treated with propranolol between November 2009 and
March 2011. Demographic data, clinical features, results of
imaging for IH, propranolol dosage, treatment outcome,
and complications were collected from medical charts.
Before initiation of propranolol treatment, comprehen-
sive history taking, vital signs, and physical examinations
were performed in all patients to confirm that there was
no associated medical history or contraindications for
propranolol, such as past cardiopulmonary disease, hyper-
active airway disease, asthma, sinus bradycardia,
secondary or third-degree heart block, cardiogenic shock,and allergy to propranolol. Treatment regimens and
potential adverse effects of propranolol were explained to
the families of the patients. Informed consent for
propranolol treatment and use of the patients’ photographs
was obtained from their parents.
The patients were first treated with 0.5e1 mg/kg/day
propranolol divided into two or three doses, and weekly
follow-up at the outpatient clinic was arranged. At each
clinic visit, baseline heart rate was recorded and the
dosage of propranolol was doubled to a maximum of
2e3 mg/kg/day as tolerated. Parental education included:
(1) observation for tachypnea, wheezing, symptoms and
signs of hypoglycemia, and signs of poor perfusion; (2)
advice on taking the drugs with or after a meal to avoid
hypoglycemia; (3) monitoring of heart rate and withholding
drugs in the event of bradycardia, defined as a heart rate
<100 beats/minute,13 and signs of poor perfusion; (4)
withholding drugs temporarily with acute illness; and (5)
making a note of any possible propranolol-associated
discomfort. During the stable course of treatment,
monthly outpatient clinic follow-up was arranged. When IH
had regressed and flattened sufficiently, propranolol was
gradually tapered over 1 month by halving the dosage each
week.
3. Results
Thirteen patients treated with 2e3 mg/kg/day propranolol
were identified between November 2009 and March 2011.
The demographic data, clinical features, imaging findings,
and treatment outcomes of these patients are summarized
in Table 1. There was a predominance of female (10/13,
76.9%) and premature (7/13, 53.8%) infants among the
patients. Seven patients (53.8%) had solitary hemangioma,
whereas the other six had multiple ones. The onset of IH in
12 patients (92.3%) occurred in the neonatal period. These
hemangiomas were located on the trunk (6/13, 46.2%),
extremity (4/13, 30.8%), face (3/13, 23.1%), scalp (3/13,
23.1%), liver (2/13, 15.4%), retro-orbital, intracranial area
and ethmoid sinus (1/13, 7.7%), neck (1/13, 7.7%), hard
palate (1/13, 7.7%), and external auditory meatus (1/13,
7.7%). No patients had thrombocytopenia, consumptive
coagulopathy or KasabacheMerritt syndrome.
The indications for treatment in our patients were
divided into four categories: (1) risk of local complication,
defined as high risk of local complication due to frequent
friction or scratching, in nine patients (69.2%, Figure 1A, 1B
and 1E); (2) functional risk, defined as impairment of vision,
hearing, feeding, or motility caused by IH, in four patients
(30.8%, Figure 1Ce1E); (3) local complication in one patient
(7.7%, painful ulceration and secondary infection with
Pseudomonas aeruginosa of hemangioma over the left
Table 1 Demographic data, clinical features, image findings, and treatment outcomes in 13 Taiwanese newborns and young infants.
Patient
no.
Age at
treatment(mo)/
sex
Age of
onset of
IH (wk)
Clinical features and image
finding of IH
Indication for
treatment
Propranolol
dosage
(mg/kg/d)
Treatment response Treatment
duration
(mo)
Last IH status/ the
interval of
discontinuation and
last follow-up
Complications
1 1/F 2 Multiple IH over left shoulder
blade (5 cm  5 cm), right
eyelid (2 cm  2 cm), scalp
(1 cm  1 cm)
Risk of local
complication
2 Decolorization: 1 wk,
regression in size: 1 wk,
stable: 5 mo
9 Stable with spot
lesions/8 mo
e
2 4/F 2 Huge IH over left hand with
painful ulceration and
secondary infection
(Pseudomonas aeruginosa)
Local
complication
2 Decolorization: 1 wk,
regression in size: 1 wk,
wound healing: 2 wk
14 Tumor flattened out
with few patch/1 mo
e
3* 1/M 4 Multifocal hepatic IH with
hepatomegaly, high output
heart failure and respiratory
distress with NCPAP support,
MDCT finding: diffuse
hypervascular tumors, largest
two tumors were 4.4 cm and
3.1 cm
Life-threatening
complication
3 Signs of heart failure
resolved: 1 wk, NCPAP
weaned off: 13 d,
regression in size: 3 mo,
tumor resolved with only
heterogenic echogenecity
by sonography: 5 mo
7 Stable with tumor
resolved completely/
2 mo
Occasional
tachypnea
4 1/F 4 IH with proptosis and
lagophthalmos, MRI finding :
huge lobulated mass over left
retro-orbital area, left ethmoid
sinus, left anterior skull base
and left posterior aspect of
suprasellar cistern
Functional risk 3 Lagophthalmos improved:
1 d, proptosis improved:
4 d, tapering at 7 mo:
relapsed 1 wk later and
restarted previous dosage
12 (ongoing) Mild proptosis/e e
5 11/F 2 IH over left subcostal abdomen,
sono finding: 2.6 cm  0.8 cm,
visible blood flow
Risk of local
complication
2.5 Decolorization: 1 wk,
regression in size: 2 wk
9 (ongoing) Regressing with one-
third previous size/e
e
6 11/F 0 IH over back, sono finding:
3.1 cm0.8 cm, visible blood
flow
Risk of local
complication
2 Decolorization: 1-2 wk,
regression in size: 2 wk
3 Stable with spot
lesions/8 months
Occasional pale
looking
7 4/F 2 Huge IH over scalp (parietal,
temporal, occipital,
preauricular area), sono finding:
multiple heterogeneous lesions
within subcutaneous layer,
maximum 3 cm0.5 cm,
enriched blood flow
Risk of local
complication
2 Decolorization: 1 wk,
regression in size: 1 wk,
stable: 4 mo
4 Stable with spot
lesions/2 months
e
8 1/F 0 Multiple IH over liver (focal,
sono finding: 1.6 cm  0.8 cm,
enriched blood flow), right
zygomatic area (sono finding:
1.1cm  0.6 cm, visible blood
flow), abdomen (2 cm  3 cm),
thorax area, left shoulder, and
neck (0.2 cm  0.3 cm)
Risk of local
complication
2 Tumor of liver resolved:
2 mo Decolorization and
regression in size of
cutaneous hemangioma:
2 wk, stable : 4 mo
4 Stable with spot
cutaneous
hemangiomas and
resolution of liver
tumor/3 mo
e
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Table 1 (continued )
Patient
no.
Age at
treatment(mo)/
sex
Age of
onset of
IH (wk)
Clinical features and image
finding of IH
Indication for
treatment
Propranolol
dosage
(mg/kg/d)
Treatment response Tre tment
dur tion
(m
Last IH status/ the
interval of
discontinuation and
last follow-up
Complications
9* 11/F 0 Huge hemagioma over right
chest wall involving breast,
sono finding: 6.7 cm  1.6 cm,
enriched blood flow
Risk of local
complication
2 Decolorization: 1 wk,
regression in size: 2 wk
5 ( going) Regressing/e e
10 3/M 0 Multiple IH over back, medial
aspect of left thigh
(2 cm  2 cm), lower half of left
leg and ankle (sono finding:
5.7 cm  0.5 cm, visible blood
flow)
Functional risk
and risk of local
complication
2 Decolorization: 10 d,
regression in size: 1 wk
5 ( going) Regressing/e e
11 6/M 0 IH over scalp, sono finding:
2.3 cm  0.6 cm,enriched blood
flow
Risk of local
complication
2 Decolorization: 3 d,
regression in size: 1 wk
3 ( going) Regressing/e e
12 4/F 0 Multiple IH over left hard palate
(3 cm  2 cm) and back
(5 cm  3 cm)
Functional risk
and risk of local
complication
2 Decolorization: 3 d,
regression in size: 3 d
3 ( going) Regressing/e e
13 8/F 8 Multiple IH over left eyelid
(sono finding:
1.7 cm  0.9 cm,enriched blood
flow, MRI finding: lobulated
mass over the left side eyelid
without orbital cavity
involvement) and left external
auditory meatus impacted
totally
Functional risk 2 Decolorization: 5 d,
regression in size: 6 d
3 ( going) Regressing/e
* Patients previously treated with corticosteroids. FZ female; IHZ infantile hemangioma; MZ male; MDCTZ multi-detector comput d tomography; NCPAPZ nasal continuous positive
airway pressure; MRI Z magnetic resonance imaging; sono Z ultrasonographic.
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Figure 1 Indications of propranolol treatment in infantile hemangiomas. (A) Risk of local complication: large hemangioma over
right chest wall involving breast in Patient 9. (B) Risk of local complication and functional risk of motility: large hemangioma over
left ankle and foot in Patient 10. (C) Functional risk of vision: ptosis and visual field defect caused by hemangioma over the left
eyelid in Patient 13. (D) Functional risk to hearing: total hemangioma impaction of left external auditory meatus in Patient 13. (E)
Risk of local complication and functional risk of feeding: hemangioma over the left hard palate caused sucking difficulty in Patient
12. (F) Local complication: infantile hemangioma with painful ulceration and secondary infection with Pseudomonas aeruginosa
over the left hand in Patient 2.
Propranolol for infantile hemangioma 129hand, fever, and leukocytosis in Patient 2, Figure 1F); and
(4) life-threatening complication in one patient (7.7%, high-
output heart failure with respiratory distress due to large
multifocal hepatic hemangioma in Patient 3).
Diagnostic imaging studies were performed in 10 patients.
Ultrasonography in eight patients revealed a mass with
visible or enriched blood flow. Multi-detector computed
tomography in Patient 3 revealed diffuse hypervascular
tumors over the liver (Figure 2A and 2B). Two tumors caused
significant arteriovenous shunting. Magnetic resonance
imaging in Patient 4 showed a huge lobulated mass over the
left orbital cavity, left ethmoid sinus, left anterior skull
base, and left posterior aspect of the suprasellar cistern
(Figure 2Ce2E).
The median age for starting propranolol treatment was 4
months, ranging from 1 to 11 months. Patients 3 and 9 were
treated with 2 mg/kg/day prednisolone for 1 week and 3
weeks, respectively. The former patient was administered
with propranolol due to progression of hemangioma-
associated heart failure, whereas the latter was shifted topropranolol due to progressive growth of hemangioma. For
the other 11 patients, propranolol was the sole treatment.
Immediate therapeutic response of superficial cutaneous
hemangiomas to propranolol, manifested as decolorization
and regression in tumor size, was observed in all patients
within 1e2 weeks after treatment. These cutaneous his
underwent further regression under current propranolol
treatment.
Therapeutic effects of propranolol on deep or visceral IH
were also seen in three patients. Patient 3 had multifocal
hepatic IH, and signs of heart failure resolved after 1 week
of treatment. The patient was weaned off continuous
positive airway pressure support after 13 days. Serial
ultrasonography was used for follow-up and revealed that
the size of the multifocal tumor had regressed after 3
months of treatment, and only heterogenic echogenicity
over the liver without nodular lesions was noted after
5 months. Patient 4 had left retro-orbital IH, and after 1
day of treatment, lagophthalmos improved. After 4 days,
there was also an improvement in proptosis. Treatment
Figure 2 Diagnostic imaging studies for infantile hemangioma in two patients. (A) Multifocal liver hemangioma in Patient 3.
Diffuse hypervascular tumors (white arrows) were mostly supplied by hepatic arteries on cross-section of multi-detector computed
tomography. (B) Some multifocal liver hemangiomas (T) in Patient 3 were seen supplied by the left gastric artery on multi-detector
computed tomography. Patient 4 had (C) huge lobulated mass with iso-signal intensity on T1-weighted imaging magnetic resonance
imaging over the left orbital cavity and left ethmoid sinus, (D) left retro-orbital hemangioma with strong contrast enhancement on
magnetic resonance imaging, and (E) similar enhancement revealed left retro-orbital hemangioma at the left anterior skull base
and left posterior aspect of suprasellar cistern (white arrow). Ao Z aorta; LGA Z left gastric artery.
130 T.-C. Hsu et alwith 3 mg/kg/day propranolol was maintained. Dosage was
tapered at 7 months after treatment, but relapse with
aggravation of proptosis was noted 1 week later. After
restarting the previous dosage of 3 mg/kg/day propranolol,
proptosis improved again.
Six patients completed the treatment course, with
a median treatment duration of 5.5 months (range: 3e14
months) (Table 1). No recurrence of IH was noted in any of
these patients during follow-up (range: 1e8 months). Seven
patients continued to receive the treatment, with a median
duration of 5 months (range: 3e12 months).
Propranolol-associated adverse effects were suspected
in two patients (15.4%). Patient 3 had occasional tachypnea
at 3 months after treatment. Patient 6 had occasional pale-
looking appearance at 1 month after treatment. These
symptoms resolved after propranolol dosage reduction. No
patient was reported to have bradycardia with poor
perfusion, and neither hypoglycemia nor hypotension was
observed.4. Discussion
Propranolol is a nonselective b-blocker and is usually used
in children for treating cardiac dysrhythmias, hypertension,
congestive heart failure, tetralogy of Fallot, thyrotoxicosis,
and migraine headache.14 In 2008, Le´aute´-Labre`ze et al
used propranolol to treat obstructive hypertrophic myo-
cardiopathy in a young infant with coexisting nasal IH, and
the hemangioma regressed rapidly and serendipitously.11
The dramatic efficacy was replicated in the other 10
infants in the same trial and in another 21 infants with
severe hemangiomas in a large follow-up observational
study.15 Propranolol was equally effective for treatment of
superficial cutaneous IH as well as for deep or visceral
IH.16e18 Rapid tumor regression within days in infants with
severe or life-threatening hemangiomas has been demon-
strated in several recent studies.12,19e23 In addition,
propranolol has been shown to be effective in cases with
IH resistant to conventional treatment with high-dose
Propranolol for infantile hemangioma 131corticosteriods, vincristine, cyclophosphamide, or inter-
feron a.24,25
Our study showed that the onset of IH was usually in
the neonatal period and all patients had received propran-
olol treatment during the proliferation phase of IH. Both
superficial cutaneous and visceral hemangioma were
dramatically responsive topropranolol treatment,whichwas
consistent with the findings of previous studies.11,15e23 In
superficial IH, decolorization and regression in tumor
size occurred within 1e2 weeks after treatment. In visceral
or deep IH, the hemangioma-associated complications
improved within 1 week. All of our IH patients continued to
show tumor regression under propranolol treatment, orwere
stabilized after discontinuation of treatment.
The exact mechanism of propranolol action on IH
remains to be clarified. It has been speculated that three
different pharmacological mechanisms of propranolol lead
to early, intermediate and long-term effects on IH.26 Early
effects are ascribed to decreased release of nitric oxide
and subsequent vasoconstriction. Intermediate effects are
believed to result from the blocking of angiogenesis
factors, including vascular endothelial growth factor, basic
fibroblast growth factor, and matrix metalloproteinase 2
and 9. Long-term effects of propranolol are thought to be
caused by the induction of apoptosis in proliferating
capillary endothelial cells. Another possible mechanism of
propranolol-induced accelerated involution proposed by
Itinteang et al involves the reduction in expression of
components of the renineangiotensin system, especially
renin and angiotensin II.27
The optimal duration of propranolol treatment in IH
has yet to be established. It is reasonable to maintain
propranolol treatment after the first year of life when the
proliferation phase is usually completed.20,21 Some inves-
tigators have evaluated the effects of discontinuation of
propranolol before the first year of age, when IH had
completely resolved.15,19 Recurrence of IH in a few patients
was reported,15,18,19 especially with abrupt withdrawal of
propranolol.23 However, reintroduction of propranolol for
recurrent growth of IH was still effective in most patients.19
In our study, four patients completed the treatment course
of propranolol before the first year of age and two dis-
continued propranolol after the proliferation phase.
Although no recurrences of IH were noted in all our
patients, larger studies are required to determine how long
the treatment should be continued.
To date, no documented death or serious cardiovascular
event has been reported for children under 6 years of age as
a direct result of b-blocker exposure.14 A few case reports
have described adverse effects of propranolol treatment
for IH, including hypoglycemia,28e30 wheezing,15 transient
hypotension,15,19,20 asymptomatic and transient brady-
cardia,25 and hyperkalemia.31 Except for one preterm
infant with potential life-threatening hyperkalemia,31
other adverse effects have been shown to resolve without
specific therapy. In our study, the patient with occasional
tachypnea after propranolol treatment had no subsequent
respiratory distress or desaturation even though the
tachypnea was thought to be related to propranolol-
induced bronchospasm. Another patient had occasional
and transient pale-looking appearance with no signs of poor
perfusion. Thus, the side effects found in our patients werenot serious. Compared with conventional agents such as
systemic corticosteroids, vincristine, and interferon a,
propranolol is a safer drug at the therapeutic dosage for IH.
However, more clinical trials are needed to provide a guide
for better monitoring of hemodynamics, blood glucose and
electrolyte status in infants with IH during the treatment
period, to prevent potential adverse effects.
Propranolol use in IH is a promising therapeutic option
with few complications. Randomized controlled studies
are necessary to determine the appropriate patient pop-
ulations, treatment dosage, treatment duration, and long-
term prognosis, as well as to investigate any long-term
adverse effects of propranolol.References
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